Macrophage Foam Cell Formation during Early Atherogenesis is Determined by the Balance between Pro-Oxidants and Anti-Oxidants in Arterial Cells and Blood Lipoproteins

Antioxidants and Redox Signaling

Volumn 1, Issue 4, 1999, Pages 585-594

  Aviram, Michael ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCYRRHIZA;

ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; ESTERASE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ARTERIOSCLEROSIS; ARTERY; BIOLOGICAL MODEL; BLOOD; CYTOLOGY; FOAM CELL; HUMAN; MACROPHAGE; METABOLISM; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANTIOXIDANTS; ARTERIES; ARTERIOSCLEROSIS; ARYLDIALKYLPHOSPHATASE; ESTERASES; FOAM CELLS; HUMANS; LIPOPROTEINS; LIPOPROTEINS, LDL; MACROPHAGES; MODELS, BIOLOGICAL; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 0033301270     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.1999.1.4-585     Document Type: Review

References (87)

1. AVIRAM, M. (1993). Modified forms of low density lipoprotein and atherosclerosis. Atherosclerosis 98, 1-9.
2. AVIRAM, M. (1995a). Oxidative modification of low density lipoprotein and atherosclerosis. Isr. J. Med. Sci. 31, 241-249.
3. AVIRAM, M. (1995b). LDL-platelet interaction under oxidative stress induces macrophage foam cell formation. Thromb. Haemost. 74, 560-564.
4. AVIRAM, M. (1996). Oxidized low density lipoprotein interaction with macrophages in atherosclerosis and the antiatherogenicity of antioxidants. Eur. J. Clin. Chem. Clin. Biochem. 34, 599-608.
5. AVIRAM, M. (1999a). Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol. Med. Today 5, 381-386.
6. AVIRAM, M. (1999b). Antioxidants in restenosis and atherosclerosis. Curr. Intervent. Cardiol. Rep. 1, 77-78.
7. AVIRAM, M., and ROSENBLAT, M. (1994). Macrophage-mediated oxidation of extra-cellular low density lipoprotein requires an initial binding of the lipoprotein to its receptor. J. Lipid. Res. 35, 385-398.
8. AVIRAM, M., and FUHRMAN, B. (1998a). LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: role of prooxidants vs. antioxidants. Mol. Cell. Biochem. 188, 149-159.
9. AVIRAM, M., and FUHRMAN, B. (1998b). Polyphenolic flavonoids inhibit macrophage-mediated oxidation of LDL and attenuate atherogenesis. Atherosclerosis 137, S45-S50.
10. AVIRAM, M., ROSENBLAT, M., ETZIONI, A., and LAVY, R. (1996). Activation of NADPH oxidase is required for macrophage-mediated oxidation of low density lipoprotein. Metabolism, 45, 1069-1079.
11. AVIRAM, M., ROSENBLAT, M., BISGAIER, C.L., NEWTON, R.S., PRIMO-PARMO, S.L., and LA DU, B.N. (1998a). Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: A possible peroxidative role for paraoxonase. J. Clin. Invest. 101, 1581-1590.
12. AVIRAM, M., BILLECKE, S., SORENSON, R., BISGAIER, C., NEWTON, R., ROSENBLAT, M., EROGUL, J., DUNLOP, C., and LA DU, B.N. (1998b). Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different than that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. 18, 1617-1624.
13. AVIRAM, M., KENT, U.M., and HOLLENBERG, P.F. (1999a). Microsomal cytochrome P450 catalyze the oxidation of low density lipoprotein. Atherosclerosis 143, 253-260.
14. AVIRAM, M., ROSENBLAT, M., BILLECKE, S., EROGUL, J., SORENSON, R., BISGAIER, C.L., NEWTON, R.S., and LA DU, B.N. (1999b). Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 26, 892-904.
15. AVIRAM, M., DORNFELD, L., ROSENBLAT, M., VOLKOVA, N., KAPLAN, M., HAYEK, T., PRESSER, D., and FUHRMAN, B. Pomegranate juice consumption reduces oxidative stress, low density lipoprotein modifications and platelet aggregation: studies in the atherosclerotic apolipoprotein E deficient mice and in humans. Am. J. Clin. Nutr., in press (a).
16. AVIRAM, M., HARDAK, E., VAYA, J., MAHMOOD, S., MILO, S., HOFFMAN, A., BILLIKE, S., DRAGONOV, D., LA DU, B., and ROSENBLAT, M. Human serum paroaoxnases (PON 1) Q and R selectively decrease lipid peroxides in coronary and carotid atherosclerotic lesions: PON 1 esterase-and peroxidase-like activities. Circulation, in press (b).
17. BELINKY, P.A., AVIRAM, M., FUHRMAN, B., ROSENBLAT, M., and VAYA, J. (1998a). The antioxidative effects of the isoflavan glabridin on endogenous constituents of LDL during its oxidation. Atherosclerosis 137, 49-61.
18. BELINKY, P.A., AVIRAM, M., MAHMOOD, S., and VAYA, J. (1998b). Structural aspects of the inhibitory effect of glabridin on LDL oxidation. Free. Radic. Biol. Med. 24, 1419-1429.
19. BERLINER, J.A., NAVAB, M., FOGELMAN, A.M., FRANK, J.S., DEMER, L.L., EDWARDS, P.A., WATSON, A.D., and LUSIS, A.J. (1995). Atherosclerosis. Basic mechanisms oxidation, inflammation, and genetics. Circulation 91, 2488-2498.
20. BERLINER, J.A., and HEINECKE, J.W. (1996). The role of oxidized lipoproteins in atherogenesis. Free Radic. Biol. Med. 20, 707-727.
21. BROWN, A.J., and JESSUP, W. (1999). Oxysterols and atherosclerosis. Atherosclerosis 142, 1-28.
22. CAMEJO, E., OLSSON, U., WIKLUND, O., BONDJERS, G., and CAMEJO, G. (1997). Cellular consequences of the association of apo B lipoproteins with protegolycans. Potential contribution to atherogenesis. Arterioscler. Thromb. Vasc. Biol. 17, 1011-1017.
23. CATHCART, M.K., LI, Q., and CHISOLM, G.M. (1995). Lipoprotein receptor interactions are not required for monocyte oxidation of LDL. J. Lipid Res. 36, 1857-1865.
24. CYRUS, T., WITZTUM, J.L., RADER, D.J., TANGIRALA, R., FAZIO, Z., LINTON, M.F., and FUNK, C.D. (1999). Disruption of the 12/15-lipoxygeanse gene diminishes atherosclerosis in apo E-deficient mice. J. Clin. Invest. 103, 1597-1604.
25. EDWARDS, I.J., GOLDBERG, I.J., PARKS, J.S., ZU, H., and WAGNER, W.D. (1993). Lipoprotein lipase enhances the interaction of low density lipoproteins with artery-derived extracellular matrix proteoglycans. J. Lipid Res. 34, 1155-1163.
26. FITZGERALD, G.A., TIGGES, J., BARRY, P., and LAWSON, J.A. (1997). Markers of platelet activation and oxidant stress in atherothrombotic disease. Thromb. Haemost. 1, 280-284.
27. FREI, B., STOCKER, R., and AMES, B.N. (1998). Antioxidant defenses and lipid peroxidation in human blood plasma. Proc. Natl. Acad. Sci. USA 85, 9748-9752.
28. FREI, B., STOCKER, R., ENGLAND, L., and AMES, B.N. (1990). Ascorbate: the most effective antioxidant in human blood plasma. Adv. Exp. Med. Biol. 264, 155-163.
29. FUHRMAN, B., OIKNINE, J., and AVIRAM, M. (1994). Iron induced lipid peroxidation in cultured macrophages increases their ability to oxidatively modify LDL and affect their secretory properties. Atherosclerosis 111, 65-78.
30. FUHRMAN, B., LAVY, A., and AVIRAM, M. (1995). Consumption of red wine with meal reduces the susceptibility of human plasma and LDL to undergo lipid peroxidation Am. J. Clin. Nutr. 61, 549-554.
31. FUHRMAN, B., OIKNINE, J., KEIDAR, S., BEN-YAISH, L., KAPLAN, M., and AVIRAM, M. (1997a). Increased uptake of LDL by oxidized macrophages is the result of an initial enhanced LDL receptor activity and of further progressive LDL oxidation. Free Radic. Biol. Med. 23, 34-46.
32. FUHRMAN, B., BUCH, S., VAYA, J., BELINKY, P.A., COLEMAN, R., HAYEK, T., and AVIRAM, M. (1997b). Licorice ethanolic extract and its major polyphenol glabridin protect LDL against lipid peroxidation: in vitro and ex-vivo studies in humans and in the atherosclerotic apolipoprotein E deficient mice. Am. J. Clin. Nutr. 66, 10-19.
33. FUHRMAN, B., BEN-YAISH, L., ATTIAS, J., HAYEK, T., and AVIRAM, M. (1997e). Tomato's lycopene and β-carotene inhibit low density lipoprotein oxidation and this effect depends on the lipoprotein vitamin E content. Nutr. Metab. Cardiovasc. Dis. 7, 433-443.
34. GRAHAM, A. (1998). Cellular thiol production and oxidation of low-density lipoprotein. Free Radic. Res. 28, 611-621.
35. GRAHAM, A., HASSAL, D.G., RAFIQUE, S., and OWEN, J.S. (1997). Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis. 135, 193-204.
36. HALLIWELL, B. (1996). Antioxidants in human health and disease. Annu. Rev. Nutr. 16, 33-50.
37. HAYEK, T., FUHRMAN, B., VAYA, J., ROSENBLAT, M., BELINKY, P., COLEMAN, R., ELIS, A., and AVIRAM, M. (1997). Reduced progression of atherosclerosis in the apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin, or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscler. Thromb. Vasc. Biol. 17, 2744-2752.
38. HEINECKE, J.W. (1998). Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis. 141, 1-15.
39. HERTOG, M.G., FESKENS, E.J., HOLLMAN, P.C., KATAN, M.B., and KORMHOUT, D. (1993). Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen elderly study. Lancet 342, 1007-1011.
40. HOLVOET, P. (1998). Oxidative modification of low-density lipoprotein in atherothrombosis. Acta. Cardiol. 53, 253-260.
41. HONDA, H.M., LEITINGER, N., FRANKEL, M., GOLDHABER, J.L., NATARAJAN, R., NADLER, J.L., WEISS, J.N., and BERLINER, J.A. (1999). Induction of monocyte binding to endothelial cells by MM-LDL: role of lipoxygenase metabolites. Arterioscler. Thromb. Vasc. Biol. 19, 680-686.
42. HURT-CAMEJO, F., OLSSON, U., WIKLUND, O., BONDJERS, G., and CAMEJO, G. (1997). Cellular consequences of the association of apo B lipoproteins with proteoglycans. Arterioscler. Thromb. Vasc. Biol. 17, 1011-1017.
43. KEIDAR, S., KAPLAN, M., HOFFMAN, A., BROOK, J.G., and AVIRAM, M. (1995). Angiotensin II stimulates macrophage-mediated lipid peroxidation of low density lipoprotein. Atherosclerosis 115, 201-215.
44. KRIEGER, M. (1997). The other side of scavenger receptors: pattern recognition for host defense. Curr. Opin. Lipidol. 8, 275-280.
45. LAPENNA, D., DE GIOIA, S., CIOFANI, G., MEZZETTI, A., UCCHINO, S., CALAFIORE, A.M., NAPOLITANO, A.M., DIILIO, C., and CUCCURULLO, F. (1998). Glutathione-related antioxidant defenses in human atherosclerotic plaques. Circulation 97, 1930-1934.
46. MACKNESS, M.I., MACKNESS, B., DURRINGTON, P.N., FOGELMAN, A.M., BERLINER, J., LUSIS, A.J., NAVAB, M., SHIH, D., and FONAROW, G.C. (1998). Paraoxonase and coronary heart disease. Curr. Opin. Lipidol. 9, 319-324.
47. MAOR, I., and AVIRAM, M. (1999). Macrophage released proteoglycans are involved in cell-mediated aggregation of LDL. Atherosclerosis 142, 57-66.
48. MAOR, I., HAYEK, T., COLEMAN, R., and AVIRAM, M. (1997). Plasma LDL oxidation leads to its aggregation in the atherosclerotic apolipoprotein E deficient mice. Arterioscler. Thromb. Vasc. Biol. 17, 2995-3005.
49. MAOR, I., HAYEK, T., HIRSH, M., IANCU, T.C., and AVIRAM, M. (1999). Macrophage released proteoglycans enhance LDL aggregation in the aorta of apolipoprotein E-deficient mice. Atherosclerosis (in press).
50. NAVAB, M., FOGELMAN, A.M., BERLINER, J.A., TERRITO, M.C., DEMER, L.L., FRANK, J.S., WATSON, A.D., EDWARDS, P.A., LUSIS, A.J. (1995). Pathogene-sis of atherosclerosis. Am J. Cardiol. 28, 18C-23C.
51. NAVAB, M., BERLINER, J.A., WATSON, A.D., HAMA, S.Y., TERRITO, M.C., LUSIS, A.J., SHIH, D.M., VAN LENTEN, B.J., FRANK, I.S., DEMER, L.L., EDWARDS, P.A., and FOGELMAN, A.M. (1996). The yin and yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler. Thromb. Vasc. Biol. 16, 831-842.
52. NAVAB, M., HAMA, S.Y., HOUGH, G.P., HEDRICK, C.C., SORENSON, R., LA DU, B.N., KOBASHIGAQA, J.A., FONAROW, G.C., BERLINER, J.A., and FOGELMAN, A.M. (1998). High density associated enzymes: their role in vascular biology. Curr. Opin Lipidol. 9, 449-456.
53. NICHOLSON, A.C., FRIEDA, S., PEARCE, A., and SILVERSTEIN, R.L. (1995). Oxidized LDL binds to CD36 on human monocyte-derived macrophages and transfected lines: evidence implicating the lipid moiety of the lipoprotein as the binding site. Arterioscler. Thromb. Vasc. Biol. 15, 269-275.
54. OORNI, K., HAKALA, J.K., ANNILA, A., ALA-KORPELA, M., and KOVANEN, P.T. (1998). Sphingomyelinase induces aggregation and fusion, but phospholipase A2 only aggregation, of low density lipoprotein (LDL) particles. Two distinct mechanisms leading to increased binding strength of LDL to human aortic proteoglycans. J. Biol. Chem. 273, 29127-29134.
55. PARTHASARATHY, S., SANTANUM, N., and AUGE, N. (1998). Oxidized low-density lipoprotein: a two-faced Janus in coronary artery disease? Biochem. Pharm. 56, 279-284.
56. PODREZ, E.A., SCHMITT, D., HOFF, H.F., and HAZEN, S.L. (1999). Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J. Clin. Invest. 103, 1547-1560.
57. 2-isoprostances in human atherosclerotic lesions. J. Clin. Invest. 100, 2028-2034.
58. PRATICO, D.T., TANGIRALA, R.K., RADER, D.J., ROCKACH, J., and FITZGERALD, G.A. (1999). Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in apo E-deficient mice. Nature Med. 10, 1189-1192.
59. ROSS, R. (1999). Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340, 115-126.
60. ROSENBLAT, M., and AVIRAM, M. (1998). Macrophage glutathione content and glutathione peroxidase activity are inversely related to cell-mediated oxidation of LDL:in vitro and in vivo studies. Free. Radic. Biol. Med. 24, 305-317.
61. ROSENBLAT, M., BELINKY, P., VAYA, J., LEVY, R., HAYEK, T., COLEMAN, R., MERCHAV, S., and AVIRAM, M. (1999). Macrophage enrichment with the isoflavan glabridin inhibits superoxide-induced cell-mediated oxidation of low density lipoprotein (LDL): A possible role for protein kinase C. J. Biol. Chem. 274, 13790-13799.
62. RUEF, J., HU, Z.Y., YIN, L.Y., WU, Y., HANSON, S.R., KELLY, A.B., HARKER, L.A., RAO, G.N., RUNGE, M.S., and PATTERSON, C. (1997). Induction of vascular endothelial growth factor in baloon-injured baboon arteries. A novel role for reactive oxygen species in atherosclerosis. Circ. Res. 1, 24-33.
63. SCHISSEL, S.L., TWEEDIE-HARDMAN, J., RAPP, J.H., GRAHAM, G., WILLIAMS, K.J., and TABAS, I. (1996). Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoprotein. J. Clin. Invest. 15, 1455-1464.
64. SCHISSEL, S.L., JIANG, X., TWEEDIE-HARDMAN, J., JEONG, T., CAMEJO, E.H., NAJIB, J., RAPP, J.H., WILLIAMS, K.J., and TABAS, I. (1998). Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J. Biol. Chem. 273, 2738-2746.
65. SMITH, C., MITCHINSON, M.J., ARUOMA, O.I., and HALLIWELL, B. (1992). Stimulation of lipid peroxidation and hydroxyl radical generation by the contents of human atherosclerotic lesions. Biochem. J. 286, 901-905.
66. STEINBERG, D. (1999). At last, direct evidence that lipoxygenases play a role in atherogenesis. J. Clin. Invest. 103, 1487-1488.
67. STEINBERG, D., PARTHASARATHY, S., CAREW, T.E., KHOO, J.C., and WITZTUM, J.L. (1989). Beyond cholesterol: modification of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320, 915-924.
68. STEINBRECHER, U.P., (1987). Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J. Biol. Chem. 262, 3603-3608.
69. STEINBRECHER, U.P. (1999). Receptors for oxidized low density lipoprotein. Biochim. Biophys. Acta 1436, 279-298.
70. STEINBRECHER, U.P., WITZTUM, J.L., PARTHASARATHY, S., and STEINBERG, D. (1987). Decrease in reactive amino groups during oxidation or endothelial cell modification of LDL. Correlation with changes in receptor-mediated catabolism. Arteriosclerosis 7, 135-143.
71. STEINBRECHER, U.P., LOUGHEED, M., KWAN, W.C., and DIRKS, M. (1989). Recognition of oxidized low density lipoprotein by the scavenger receptor of macro-phages results from derivatization of apolipoprotein B by products of fatty acid peroxidation. J. Biol. Chem. 264, 15216-15223.
72. STOCKER, R., BOWRY, V.W., and FREI, B. (1991). Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc. Natl. Acad. Sci. USA 89, 1646-1650.
73. TABAS, I., LI, Y., BROCIA, R.W., WX, S.W., SWENSON, T.L., and WILLIAMS, K.J. (1993). Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein (a) retention and macrophage foam cell formation. J. Biol. Chem. 268, 20419-20432.
74. TANGIRALA, R.K., MOL, M.J., and STEINBERG, D. (1996). Macrophage oxidative modification of low density lipoprotein occurs independently of its binding to the LDL receptor. J. Lipid Res. 37, 835-843.
75. UPSTON, J.M., TERENTIS, A.C., and STOCKER, R. (1999). Tocopherol-mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement. FASEB J. 13, 977-994.
76. UYEMURA, K., DEMER, L.L., CASTLE, S.C., JULLIEN, D., BERLINER, J.A., GATELY, M.K., WARRIER, R.R., PHAM, N., FOGELMAN, A.M., and MODLIN, R.L. (1996). Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J. Clin. Invest. 97, 2130-2138.
77. VAN ACKER, S.A., VAN DEN BERG, D.J., TROMP, M.N., GRIFFIGEN, D.H., VAN BENNEKOM, W.P., VAN DER VIJGH, W.J., and BAST, A. (1996). Structural aspects of antioxidant activity of flavonoids. Free. Radic. Biol. Med. 20, 331-342.
78. VAN LENTEN, B.J., PRIEVE, J., NAVAB, M., HAMA, S., LUSIS, A.J., and FOGELMAN, A.M., (1995). Lipid-induced changes in intracellular iron homeostasis in vitro and in vivo. J. Clin. Invest. 95, 2104-2110.
79. VAYA, J., BELINKI, P., and AVIRAM, M. (1997). Antioxidant constituents from licorice roots: isolation, structure elucidation and antioxidative capacity towards LDL oxidation. Free. Radic. Biol. Med. 23, 302-312.
80. WATSON, A.D., BERLINER, J.A., HAMA, S.Y., LA DU, B.N., FAULL, K.F., FOGELMAN, A.M., and NAVAB, M. (1995). Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96, 2882-2891.
81. WATSON, A.D., LEITINGER, N., NAVAB, M., FAULL, K.F., HORKKO, S., WITZTUM, J.L., PALINSKI, W., SCHWENKE, D., SALOMO, R.G., SHA, W., SUBBANAGOUNDER, G., FOGELMAN, A.M., and BERLINER, J.A. (1997). Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induced monocyte-endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272, 13597-13607.
82. WELCH, G.N., UPCHURCH, G.R., JR., and LOSCALZO, J. (1997). Homocysteine, oxidative stress, and vascular disease. Hosp. Pract. 32, 88-92.
83. WILLIAMS, K.J., and TABAS, I. (1995). The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15, 551-561.
84. WITTING, P.K., PETTERSSON, K., OSTLUND-LINDQVIST, A.M., WESTERLUND, C., ERIKSSON, A.W., and STOCKER, R. (1999). Inhibition by a coantioxidant of aortic lipoprotein lipid peroxidation and atherosclerosis in apolipoprotein E and low density lipoprotein receptor gene double knockout mice. FASEB J. 13, 667-675.
85. WITZTUM, J.L., and BERLINER, J.A. (1998). Oxidized phospholipids and isoprostanes in atherosclerosis. Curr. Opin. Lipidol. 9, 441-448.
86. YUAN, X.M., BRUNK, U.T., and OLSSON, A.G. (1995). Effects of iron-and hemoglobin-loaded human monocyte-derived macrophages on oxidation and uptake of LDL. Arterioscler. Thromb. Vasc. Biol. 15, 1345-1351.
87. YUAN, X.M., ANDERS, W.L., OLSSON, A.G., and BRUNK, U.T. (1996). Iron in human atheroma and LDL oxidation by macrophages following erythrophagocytosis. Atherosclerosis 124, 61-73.